-
CSR Summary
Not Available
-
NCT01606228
-
Primary Citation
Trial has yet to be published
-
Data Specification
Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NamePaliperidoneProduct NameINVEGA®Therapeutic AreaBehaviors and Mental DisordersEnrollment188% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR076477SCH3033Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A
Supporting Documentation
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Additional Information
Please note: individual participant-level data are not available for this trial. Only the protocol, statistical analysis plan, and clinical study report are available.
Approved Data Requests Associated with this Trial
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2016-0766 : Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials
- 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques